Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong Mu

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <i>FLT3</i>-Mutant Acute Myeloid LeukemiaXuejie Jiang, Po Yee Mak, Hong Mu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung CancerMitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Leukemia|May 26, 2019
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemiaTakenobu Nii, Varun V Prabhu, Vivian Ruvolo, et al.
Journal for Immunotherapy of Cancer|October 28, 2025
Genetic haplotypes in <i>VWA8, OSBPL6,</i> and <i>ADAMTS9-AS2</i> are associated with immune-related adverse effects in ICI-treated patients with cancerPrithvi Raj, Jialiang Liu, Chengsong Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid LeukemiaLina Han, Jeffrey L Jorgensen, Chris Brooks, et al.
JTO Clinical and Research Reports|December 2, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung CancerMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Differences in systemic immune parameters in individuals with lung cancer according to raceMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Oncotarget|March 1, 2018
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in <i>CRLF2</i> rearranged and/or <i>JAK</i> driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemiaQi Zhang, Ce Shi, Lina Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Journal for Immunotherapy of Cancer|September 10, 2025
Innate and adaptive immune features associated with immune-related adverse eventsShaheen Khan, Venkat S Malladi, Mitchell S von Itzstein, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <i>FLT3</i>-Mutant Acute Myeloid LeukemiaXuejie Jiang, Po Yee Mak, Hong Mu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung CancerMitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Leukemia|May 26, 2019
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemiaTakenobu Nii, Varun V Prabhu, Vivian Ruvolo, et al.
Journal for Immunotherapy of Cancer|October 28, 2025
Genetic haplotypes in <i>VWA8, OSBPL6,</i> and <i>ADAMTS9-AS2</i> are associated with immune-related adverse effects in ICI-treated patients with cancerPrithvi Raj, Jialiang Liu, Chengsong Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid LeukemiaLina Han, Jeffrey L Jorgensen, Chris Brooks, et al.
JTO Clinical and Research Reports|December 2, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung CancerMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Differences in systemic immune parameters in individuals with lung cancer according to raceMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Oncotarget|March 1, 2018
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in <i>CRLF2</i> rearranged and/or <i>JAK</i> driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemiaQi Zhang, Ce Shi, Lina Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Journal for Immunotherapy of Cancer|September 10, 2025
Innate and adaptive immune features associated with immune-related adverse eventsShaheen Khan, Venkat S Malladi, Mitchell S von Itzstein, et al.
Pageof 21